InvestSMART

Raptor Metals Ltd (ASX: RAP) - Announcements

- Current share price for RAP : $0.023

ASX company news and announcements for Raptor Metals Ltd (RAP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Raptor Metals Ltd (RAP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Raptor Metals Ltd (RAP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Raptor Metals Ltd (RAP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$9 ResApp Provides Update on SMARTCOUGH-C-2 Study Timing 27 Sep 2018 8:42AM $0.210 $0.023 fallen by 89.05%
$9 Appendix 3B & Section 708A Notice 24 Sep 2018 9:36AM $0.245 $0.023 fallen by 90.61%
$9 Change in substantial holding 21 Sep 2018 8:20AM $0.235 $0.023 fallen by 90.21%
$9 ResApp Successfully Completes $7.5 Million Capital Raising 19 Sep 2018 9:40AM $0.270 $0.023 fallen by 91.48%
$9 Trading Halt 17 Sep 2018 9:49AM $0.270 $0.023 fallen by 91.48%
$9 Company Update Presentation 12 Sep 2018 8:34AM $0.235 $0.023 fallen by 90.21%
$9 Positive Results for Australian Prospective Paediatric Study 3 Sep 2018 9:48AM $0.195 $0.023 fallen by 88.21%
$9 Trading Halt 31 Aug 2018 9:14AM $0.195 $0.023 fallen by 88.21%
$9 Appendix 4E - Preliminary Final Report 31 Aug 2018 8:47AM $0.195 $0.023 fallen by 88.21%
$9 ResApp Partners with Lockheed Martin for DARPA Research 16 Aug 2018 9:12AM $0.180 $0.023 fallen by 87.22%
$9 Notice of Acceptance Received for Core Patent in Australia 15 Aug 2018 9:23AM $0.175 $0.023 fallen by 86.86%
$9 Broker Meets Biotech Presentation 9 Aug 2018 9:27AM $0.225 $0.023 fallen by 89.78%
$9 Enrolment Completed in Australian Paediatric Clinical Study 2 Aug 2018 9:42AM $0.165 $0.023 fallen by 86.06%
$9 ResApp Completes Enrolment of SMARTCOUGH-C-2 Study 1 Aug 2018 9:30AM $0.140 $0.023 fallen by 83.57%
$9 Quarterly Update and Appendix 4C 31 Jul 2018 4:15PM $0.140 $0.023 fallen by 83.57%
$9 ResApp Provides Obstructive Sleep Apnoea Study Update 12 Jul 2018 9:06AM $0.115 $0.023 fallen by 80%
$9 ResApp Provides Update on Australian Clinical Study 28 Jun 2018 9:41AM $0.130 $0.023 fallen by 82.31%
$9 ResApp Receives Notice of Allowance for Core Patent in US 6 Jun 2018 11:41AM $0.145 $0.023 fallen by 84.14%
$9 ResApp Provides SMARTCOUGH-C-2 Study Update 31 May 2018 8:49AM $0.135 $0.023 fallen by 82.96%
$9 Quarterly Update and Appendix 4C 30 Apr 2018 8:24AM $0.150 $0.023 fallen by 84.67%
$9 Corporate Governance Statement 27 Apr 2018 5:41PM $0.150 $0.023 fallen by 84.67%
$9 ResApp Receives R&D Tax Incentive Cash Rebate for FY17 26 Apr 2018 9:20AM $0.150 $0.023 fallen by 84.67%
$9 ResApp Signs LOI with German Private Hospital Network 24 Apr 2018 9:34AM $0.140 $0.023 fallen by 83.57%
$9 Response to ASX Aware Letter 16 Apr 2018 11:35AM $0.165 $0.023 fallen by 86.06%
$9 Investor Conference Call 12 Apr 2018 8:37AM $0.160 $0.023 fallen by 85.63%

351 - 375 of 576 results

Page 15 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.